Study of DS-7080a for the Treatment of Macular Degeneration
Public ClinicalTrials.gov record NCT02530918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema
Study identification
- NCT ID
- NCT02530918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Daiichi Sankyo
- Industry
- Enrollment
- 56 participants
Conditions and interventions
Interventions
- DS-7080a Drug
- Ranibizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2015
- Primary completion
- Jan 1, 2018
- Completion
- Jan 1, 2018
- Last update posted
- May 8, 2018
2015 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85014 | — |
| Not listed | Arcadia | California | 91007 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Palm Desert | California | 92260 | — |
| Not listed | Fort Myers | Florida | 33912 | — |
| Not listed | Baltimore | Maryland | 21237 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Omaha | Nebraska | 68105 | — |
| Not listed | Abilene | Texas | 79606 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | San Antonio | Texas | 78240 | — |
| Not listed | Silverdale | Washington | 98383 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02530918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2018 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02530918 live on ClinicalTrials.gov.